11β-hydroxylase deficiency epidemiology and demographics

Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
11β-hydroxylase deficiency epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of 11β-hydroxylase deficiency epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on 11β-hydroxylase deficiency epidemiology and demographics
CDC on 11β-hydroxylase deficiency epidemiology and demographics
11β-hydroxylase deficiency epidemiology and demographics in the news
Blogs on 11β-hydroxylase deficiency epidemiology and demographics
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency
Risk calculators and risk factors for 11β-hydroxylase deficiency epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

The prevalence of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency is approximately 1 per 100,000 individuals the United States. Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency affects males and females equally. Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency usually affects individuals of the Jewish race.

Epidemiology and Demographics

Prevalence

• The prevalence of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency in the United States is approximately 1 per 100,000 individuals.

Incidence

• Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency accounts for 5 to 8 percent of all cases of congenital adrenal hyperplasia. It is estimated that congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency occurs in 1 in 100,000 to 200,000 newborns. This condition is more common in Moroccan Jews living in Israel, occurring in approximately 1 in 5,000 to 7,000 newborns.

Case Fatality Rate

• The case­ fatality rate of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency is highest.

Age

• Patients of all age groups may develop congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. The mean age of diagnosis is infancy and childhood.

Gender

• Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency affects males and females equally.

Race

• Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency usually affects individuals of the Jewish race.

References

Template:WikiDoc Sources